mAbRx, Inc.

mAbRx, is developing therapeutic antibodies using a patented technology called Exosome Display. The originality of the technology enables the generation of antibodies against relevant pharmaceutical targets for which traditional antibody generation methods are challenging. This positions mAbRx in a unique niche of product development as it fills an important unmet need in the field of antibody generation. mAbRx competitiveness is further enhanced by the broad range of the technology for applications in diverse fields including vaccine and targeted drug delivery of proteins, RNAs, and lipids.

Through collaborations with laboratories of renowned institutions using relevant pharmaceutical targets, mAbRx has established the efficiency of its technology to generate antibody responses against challenging antigens. Two of these antibodies are currently part of the company product pipeline for drug development.

The unique and powerful feature of the technology for antibody generation stems from harnessing the exosome pathway, which is the natural antigen delivery pathway, to break tolerance against highly conserved or “self“ therapeutic targets. This enables the generation of efficient therapeutic candidates against immunologically challenging but important pharmaceutical targets such as GPCRs, RORs, ion channels and tumor antigens.